Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
1(20%)
Results Posted
33%(1 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_2
1
20%
Ph phase_1
3
60%
Ph phase_4
1
20%

Phase Distribution

3

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 4Post-market surveillance
1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(3)
Terminated(1)

Detailed Status

Completed3
Active, not recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
75.0%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (60.0%)
Phase 21 (20.0%)
Phase 41 (20.0%)

Trials by Status

completed360%
active_not_recruiting120%
terminated120%

Recent Activity

1 active trials
Showing 5 of 5
active_not_recruitingphase_1

First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107e/CAF®10b

NCT06050356
completedphase_4

Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses

NCT04276259
completedphase_1

Safety and Immunogenicity of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine

NCT05027932
completedphase_1

Safety and Immunogenicity of Cam2020 M2SR H3N2 Monovalent Influenza Vaccine Alone or With Licensed IIV in Older Adults

NCT05163847
terminatedphase_2

Efficacy Study of Adrenocorticotropin Hormone to Treat Multiple Sclerosis (MS) Relapses After Sub-responding to an Initial 3 Day Course of Intravenous (IV) Methylprednisolone

NCT00947895

Clinical Trials (5)

Showing 5 of 5 trials
NCT06050356Phase 1

First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107e/CAF®10b

Active Not Recruiting
NCT04276259Phase 4

Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses

Completed
NCT05027932Phase 1

Safety and Immunogenicity of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine

Completed
NCT05163847Phase 1

Safety and Immunogenicity of Cam2020 M2SR H3N2 Monovalent Influenza Vaccine Alone or With Licensed IIV in Older Adults

Completed
NCT00947895Phase 2

Efficacy Study of Adrenocorticotropin Hormone to Treat Multiple Sclerosis (MS) Relapses After Sub-responding to an Initial 3 Day Course of Intravenous (IV) Methylprednisolone

Terminated

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5